Tuberculosis news from FierceVaccines
NewsCrucell reports early-stage success with TB vaccine
Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is Read more...
Sanofi licenses technology for new TB vaccine
Sanofi Pasteur has struck a licensing deal with the Statens Serum Institut of Denmark covering the use of its technology for a new tuberculosis vaccine. The pact includes SSI's Intercell IC31 Read more...
| Press ReleasesPRESS RELEASE: New Antibiotic Drug Combo To Speed Up Treatment of Tuberculosis New Antibiotic Drug Combo To Speed Up Treatment of Tuberculosis (Scheduled for presentation at 8:30 a.m. CDT/9:30 a.m. EDT, Tuesday, Sept. 18; oral presentation #L-736A, Room E450B, McCormick Place Read more... |
Get more Tuberculosis coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight